Purpose: This study aimed to develop and validate a model based on machine learning algorithms to predict the risk of in-hospital death among advanced elderly patients with Heart Failure (HF). Methods: A total of 4580 advanced elderly patients who were admitted to the hospital and diagnosed with HF from May 2012 to September 2023 were included in this study, among whom 552 cases (12.5%) died. The least absolute shrinkage and selection operator (LASSO) regression and Boruta feature selection were used to screen the baseline variables to identify the variables significantly associated with death. Subsequently, seven different machine learning models were constructed and their prediction performances were evaluated. The Shapley Additive Explanations (SHAP) values were used to analyze the impact of key variables on the model prediction results. Results: A total of seven variables significantly associated with death were selected by LASSO regression and Boruta feature selection, including white blood cell count (WBC), neutrophil percentage (Neut %), C-reactive protein (CRP), D-dimer, glycated serum protein (GSP), N-terminal pro-B-type natriuretic peptide (NT-ProBNP), and body mass index (BMI). Among all the models, the extreme gradient boosting (XGB) model performed the best, with an area under the curve (AUC) value of 0.933, a sensitivity of 0.79, a specificity of 0.89, a recall of 0.79, and an F1 score of 0.59 on the validation set. The SHAP analysis showed that CRP, BMI, NT-ProBNP, D-dimer, and GSP were the main influencing factors for death. Conclusion: This study successfully constructed a prediction model for the in-hospital death risk of advanced elderly patients with HF, and the XGB model exhibited excellent prediction performance. This model can be used for the early clinical identification of high-risk patients and thus provide support for individualized treatment strategies.
4 August 2022 in International Journal of Cardiology
Background: Atrial fibrillation (AF) is a common arrhythmia disorder with a high recurrence rate after catheter ablation for pulmonary vein isolation (PVI). Improved preoperative evaluation strategies are needed to enhance prediction accuracy and optimize patient selection for ablation. Materials and Methods: This study included 311 AF patients who underwent catheter ablation for PVI, stratified into recurrence ( n = 160) and non-recurrence ( n = 151) groups based on postoperative outcome. The deep learning model SwinUNETR was used to segment the heart region and extract the radiomics features of different areas of the heart. A risk prediction model was built using six machine learning methods. Finally, an interpretable analysis method based on radiomics was provided to capture the relationship between the radiological features of different heart structures and the recurrence of AF. Results: A feature selection process was applied to determine the most predictive features, resulting in a set of 50 radiomics features and 33 clinical features. The average dice value of the deep learning heart segmentation model was 88.95%, and the area under the curve (AUC) value of the radiomics model for predicting the risk of AF recurrence after PVI was 0.74(95% confidence interval (CI) 0.54, 0.79). The AUC value of the fusion model integrating clinical laboratory indicators and radiomic features was 0.79(95% CI 0.69–0.84). According to the results of the interpretability analysis of the model, multiple radiomics features were determined to be significantly associated with AF recurrence. Conclusion: This study presents a non-invasive model for predicting post-PVI recurrence and quantifies the contribution of specific cardiac structures to AF recurrence risk.
Background While the guidelines acknowledge the anticipated benefits of using an implantable cardioverter defibrillator (ICD) in individuals with catecholaminergic polymorphic ventricular tachycardia (CPVT). However, the potential adverse effects have received less attention. Methods and analysis To address this issue comprehensively, we will explore various databases such as the Cochrane Library, Web of Science, EMBASE and PubMed. Our study will include CPVT patients, both with and without ICD implantation. Two researchers will evaluate the eligible studies independently and gather pertinent data. The quality of the studies included will be assessed using either the Newcastle-Ottawa Scale or the Cochrane Risk of Bias Tool. Data analysis will be conducted using RevMan. Ethics and dissemination Because this research depends exclusively on existing studies, obtaining patient informed consent and ethics approval is unnecessary. The results of this meta-analysis will be shared at conferences or in peer-reviewed journals. PROSPERO registration number CRD42022370824.
4 August 2022 in International Journal of Cardiology